Fine Foods & Pharmaceuticals NTM SpA
MIL:FF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.8
9.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fine Foods & Pharmaceuticals NTM SpA
Total Current Liabilities
Fine Foods & Pharmaceuticals NTM SpA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Fine Foods & Pharmaceuticals NTM SpA
MIL:FF
|
Total Current Liabilities
€67.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
||
Stevanato Group SpA
NYSE:STVN
|
Total Current Liabilities
€574.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Fine Foods & Pharmaceuticals NTM SpA
Glance View
Fine Foods & Pharmaceuticals N.T.M. The company is headquartered in Verdellino, Bergamo and currently employs 768 full-time employees. The company went IPO on 2016-10-19. The company is specialized in the manufacturing of pharmaceutical products for third parties. The firm manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.
See Also
What is Fine Foods & Pharmaceuticals NTM SpA's Total Current Liabilities?
Total Current Liabilities
67.6m
EUR
Based on the financial report for Jun 30, 2024, Fine Foods & Pharmaceuticals NTM SpA's Total Current Liabilities amounts to 67.6m EUR.
What is Fine Foods & Pharmaceuticals NTM SpA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
9%
Over the last year, the Total Current Liabilities growth was -24%. The average annual Total Current Liabilities growth rates for Fine Foods & Pharmaceuticals NTM SpA have been 6% over the past three years , 9% over the past five years .